Ventyx Biosciences, Inc. (VTYX:NASDAQ) closed at $14.00 on March 3, 2026, unchanged on the day. The stock trades 44.0% below its 52-week high of $25.00 and 1,688.0% above its 52-week low of $0.783. Ventyx Biosciences, Inc. is part of the Health Care sector.
In 252 trading sessions since October 22, 2025, VTYX closed higher on 49 days (19%). Its best day was October 23, 2025 (+70.98%) and its worst was December 2, 2025 (-15.35%). The stock moved 10% or more in a single session 10 times. It opened at least 5% above the previous day's high 1 time.
Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune disorders. Its lead product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors.
Find more stocks like VTYX with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.